Abstract
Cells grow in response to nutrients or growth factors, whose presence is detected and communicated by elaborate signaling pathways. Protein kinases play crucial roles in processes such as cell cycle progression and gene expression, and misregulation of such pathways has been correlated with various diseased states. Signals intended to promote cell growth converge on ribosome biogenesis, as the ability to produce cellular proteins is intimately tied to cell growth. Part of the response to growth signals is therefore the coordinate expression of genes encoding ribosomal RNA (rRNA) and ribosomal proteins (RP). A key player in regulating cell growth is the Target of Rapamycin (TOR) kinase, one of the gatekeepers that prevent cell cycle progression from G1 to S under conditions of nutritional stress. TOR is structurally and functionally conserved in all eukaryotes. Under favorable growth conditions, TOR is active and cells maintain a robust rate of ribosome biogenesis, translation initiation and nutrient import. Under stress conditions, TOR signaling is suppressed, leading to cell cycle arrest, while the failure of TOR to respond appropriately to environmental or nutritional signals leads to uncontrolled cell growth. Emerging evidence from Saccharomyces cerevisiae indicates that High Mobility Group (HMGB) proteins, non-sequence-specific chromosomal proteins, participate in mediating responses to growth signals. As HMGB proteins are distinguished by their ability to alter DNA topology, they frequently function in the assembly of higher-order nucleoprotein complexes. We review here recent evidence, which suggests that HMGB proteins may function to coordinate TOR-dependent regulation of rRNA and RP gene expression.
Keywords: Rapamycin, TORC1, HMO1, high mobility group, yeast, RP gene, rDNA
Current Genomics
Title: Coordination of Ribosomal Protein and Ribosomal RNA Gene Expression in Response to TOR Signaling
Volume: 10 Issue: 3
Author(s): LiJuan Xiao and Anne Grove
Affiliation:
Keywords: Rapamycin, TORC1, HMO1, high mobility group, yeast, RP gene, rDNA
Abstract: Cells grow in response to nutrients or growth factors, whose presence is detected and communicated by elaborate signaling pathways. Protein kinases play crucial roles in processes such as cell cycle progression and gene expression, and misregulation of such pathways has been correlated with various diseased states. Signals intended to promote cell growth converge on ribosome biogenesis, as the ability to produce cellular proteins is intimately tied to cell growth. Part of the response to growth signals is therefore the coordinate expression of genes encoding ribosomal RNA (rRNA) and ribosomal proteins (RP). A key player in regulating cell growth is the Target of Rapamycin (TOR) kinase, one of the gatekeepers that prevent cell cycle progression from G1 to S under conditions of nutritional stress. TOR is structurally and functionally conserved in all eukaryotes. Under favorable growth conditions, TOR is active and cells maintain a robust rate of ribosome biogenesis, translation initiation and nutrient import. Under stress conditions, TOR signaling is suppressed, leading to cell cycle arrest, while the failure of TOR to respond appropriately to environmental or nutritional signals leads to uncontrolled cell growth. Emerging evidence from Saccharomyces cerevisiae indicates that High Mobility Group (HMGB) proteins, non-sequence-specific chromosomal proteins, participate in mediating responses to growth signals. As HMGB proteins are distinguished by their ability to alter DNA topology, they frequently function in the assembly of higher-order nucleoprotein complexes. We review here recent evidence, which suggests that HMGB proteins may function to coordinate TOR-dependent regulation of rRNA and RP gene expression.
Export Options
About this article
Cite this article as:
Xiao LiJuan and Grove Anne, Coordination of Ribosomal Protein and Ribosomal RNA Gene Expression in Response to TOR Signaling, Current Genomics 2009; 10 (3) . https://dx.doi.org/10.2174/138920209788185261
DOI https://dx.doi.org/10.2174/138920209788185261 |
Print ISSN 1389-2029 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5488 |
Call for Papers in Thematic Issues
Current Genomics in Cardiovascular Research
Cardiovascular diseases are the main cause of death in the world, in recent years we have had important advances in the interaction between cardiovascular disease and genomics. In this Research Topic, we intend for researchers to present their results with a focus on basic, translational and clinical investigations associated with ...read more
Deep learning in Single Cell Analysis
The field of biology is undergoing a revolution in our ability to study individual cells at the molecular level, and to integrate data from multiple sources and modalities. This has been made possible by advances in technologies for single-cell sequencing, multi-omics profiling, spatial transcriptomics, and high-throughput imaging, as well as ...read more
New insights on Pediatric Tumors and Associated Cancer Predisposition Syndromes
Because of the broad spectrum of children cancer susceptibility, the diagnosis of cancer risk syndromes in children is rarely used in direct cancer treatment. The field of pediatric cancer genetics and genomics will only continue to expand as a result of increasing use of genetic testing tools. It's possible that ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Use of Transient Expression Systems for the Rapid Production of Virus-like Particles in Plants
Current Pharmaceutical Design Denosumab: The Era of Targeted Therapies in Bone Metastatic Diseases
Current Cancer Drug Targets Histidine Rich Glycoprotein, an Endogenous Regulator of Macrophage and Endothelial Biology
Current Angiogenesis (Discontinued) Nur77 Family of Nuclear Hormone Receptors
Current Drug Targets - Inflammation & Allergy Proinflammatory Cytokines in Breast Cancer: Mechanisms of Action and Potential Targets for Therapeutics
Current Drug Targets Patent Selections
Recent Patents on Anti-Cancer Drug Discovery Advances in Peptide-based Human Papillomavirus Therapeutic Vaccines
Current Topics in Medicinal Chemistry Androgen Metabolic Pathway Involved in Current and Emerging Treatment for Men with Castration Resistant Prostate Cancer: Intraprostatic Androgens as Therapeutic Targets and Endocrinological Biomarkers
Current Drug Targets Microwave-induced Bismuth Salts-mediated Synthesis of Molecules of Medicinal Interests
Current Medicinal Chemistry Cytotoxic Thiol Alkylators
Mini-Reviews in Medicinal Chemistry Nitric Oxide and Disorders of the Erythrocyte: Emerging Roles and Therapeutic Targets
Cardiovascular & Hematological Disorders-Drug Targets Calcium as a Molecular Target in Angiogenesis
Current Pharmaceutical Design Transdermal Delivery of 5-Fluorouracil for Induced Ehrlich Ascites Carcinoma Tumor in Balb/c Mice and Pharmacokinetic Study
Recent Patents on Anti-Cancer Drug Discovery Epigenetic Regulation of EMT in Non-Small Cell Lung Cancer
Current Cancer Drug Targets Recent Advances on Radionuclide Labeled Hypoxia-Imaging Agents
Current Pharmaceutical Design The TGF-β Signaling Pathway as a Pharmacological Target in a Hepatocellular Carcinoma
Current Pharmaceutical Design New Perspective on the Dual Functions of Indirubins in Cancer Therapy and Neuroprotection
Anti-Cancer Agents in Medicinal Chemistry Topical Antimicrobials for Burn Wound Infections
Recent Patents on Anti-Infective Drug Discovery Pharmacokinetics-Guided Dosing of 5-Fluorouracil for Precision Cancer Treatment: A Focus on Colorectal Carcinoma
Applied Clinical Research, Clinical Trials and Regulatory Affairs Meet Our Editorial Board Member
Current Cancer Drug Targets